Claritev Corporation Announces Participation in Canaccord Genuity 46th Annual Growth Conference

MCLEAN, Va.--(BUSINESS WIRE)-- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, including a fireside chat on Tuesday, August 11, 2026, at 10:00am ET.

A live webcast and audio archive of the event will be available through the investor relations section of Claritev’s website at https://investors.claritev.com/news-events/events.

About Claritev

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804518391/en/

Investor Relations Contact
Todd Friedman
VP, Investor Relations
Claritev
[email protected]

Media Contact
Jen O’Connor
VP, Brand Marketing
Claritev
[email protected]

Source: Claritev Corporation

You May Also Be Interested In

• Janus Henderson Further Bolsters Global Equities Franchise with Two Senior Investment Appointments
• Fingerprint Launches Bot Directory Built for the AI Era
• CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis